News & Events
Coming soon with more information.
Sleep disorders is recognized as a symptom of heart failure, blood pressure and other diseases. To-date there are more than 45 million Americans who suffer from sleep disorders of which half is Obstructive Sleep Apnea (OSA). The US sleep diagnostics market (only) is estimated at $2.5B with annual growth of 20%.
Manual scoring relies on standard R&K scoring rules to identify specific waveforms and quantify their duration by a human scorer. This process is time consuming and subject to variability in interpretation.
These facts are the drivers for the growing demand for enhanced automated diagnostics equipment derived of accurate sleep bio-signal analysis.
WideMed has been active in the sleep industry since 2000. During this time, the company has been fully dedicated to sleep bio-signal analysis.
The company’s extensive knowledge in the sleep industry has enabled WideMed to develop an innovative, patent pending and robust sleep analysis providing more insight into pharmaceutical effects on insomnia, sleep quality and other CNS disorders.
Bringing theory knowledge into reality, WideMed developed the first FDA approved computer-aided scoring system – Morpheus. It is a combined system that offers a synergy between standard web-based data mining platform and an innovative bio medical sleep analysis, using clinical rules by which the analysis engine scores the signals can be customized according to the customer’s preference.